Spravato Begins Working Within 24 Hours
Spravato (esketamine) nasal spray demonstrates significant improvement in depressive symptoms within 24 hours after the first dose, with most of the treatment difference compared to placebo observed at this early timepoint. 1
Timeline of Therapeutic Effect
Immediate Response (24 Hours)
The FDA label for Spravato clearly shows that most of the treatment difference compared to placebo was observed at 24 hours after the first administration 1. This rapid onset distinguishes esketamine from traditional oral antidepressants, which typically require 4-8 weeks to demonstrate efficacy 2.
Recent real-world evidence confirms this rapid effect, with mobile app monitoring demonstrating significant reduction in depressive symptoms 1 day after the first administration 3.
Progressive Improvement (Days 2-28)
- Day 2 (24 hours post-first dose): Statistically significant improvement with effect sizes of -3.8 for 56mg and -3.4 for 84mg doses 4
- Days 3-4: Improvements persist 5
- Day 28: Maximum effect achieved during induction phase, with effect sizes of 0.48 (56mg) and 0.63 (84mg) 4
Important clinical note: Between 24 hours and Day 28, both esketamine and placebo groups continue to improve, but the difference between groups generally remains stable rather than increasing 1. This suggests the rapid initial benefit is maintained but doesn't substantially expand during the 4-week induction phase.
Clinical Context from Guidelines
The 2022 VA/DoD guidelines emphasize that ketamine (the racemic mixture) showed significant improvement in depressive symptoms after 24 hours in treatment-resistant depression, with improvements persisting at 3- and 4-day follow-up visits 5. For esketamine specifically, twice-weekly dosing as augmentation to oral antidepressants improved depressive symptoms at up to 28 days of follow-up 5.
Long-Term Response Pattern
Real-world data reveals that while initial response occurs rapidly, progressive improvements often consolidate beyond the induction phase, especially during the optimization phase (weeks 8-16) 6. The median time to response was 8 weeks, and to remission was 16 weeks in routine clinical practice 6.
Critical Monitoring Requirements
Because of the rapid onset, patients require mandatory monitoring for 2 hours after each treatment due to risk evaluation and mitigation strategy (REMS) requirements 5. The most common adverse events (dissociation, nausea, vertigo, dizziness) appear shortly after dosing and typically resolve by 1.5 hours post-administration 7.
Clinical Pitfalls to Avoid
- Don't expect continuous linear improvement: The treatment difference plateaus after 24 hours rather than progressively increasing through Day 28
- Don't discontinue prematurely: While initial response is rapid, full remission may take 8-16 weeks in real-world settings 6
- Don't use as monotherapy initially: Esketamine is approved and most effective when combined with an oral antidepressant, though recent data supports monotherapy efficacy 4